Invalid Symbol

Stock Research for RPRX

Current Price


Latest Update:


Featured Broker: TradeStation

Get the due diligence for another stock.


RPRX Stock Chart & Research Data

The RPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


RPRX Due diligence Resources & Stock Charts

The RPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RPRX Detailed Price Forecast - CNN Money CNN View RPRX Detailed Summary - Google Finance
Yahoo View RPRX Detailed Summary - Yahoo! Finance Zacks View RPRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View RPRX Trends & Analysis - Trade-Ideas Barrons View RPRX Major Holders - Barrons
NASDAQ View RPRX Call Transcripts - NASDAQ Seeking View RPRX Breaking News & Analysis - Seeking Alpha
Spotlight View RPRX Annual Report - OTC Report View RPRX OTC Short Report -
TradeKing View RPRX Fundamentals - TradeKing Charts View RPRX SEC Filings - Bar Chart
WSJ View Historical Prices for RPRX - The WSJ Morningstar View Performance/Total Return for RPRX - Morningstar
MarketWatch View the Analyst Estimates for RPRX - MarketWatch CNBC View the Earnings History for RPRX - CNBC
StockMarketWatch View the RPRX Earnings - StockMarketWatch MacroAxis View RPRX Buy or Sell Recommendations - MacroAxis
Bullish View the RPRX Bullish Patterns - American Bulls Short Pains View RPRX Short Pain Metrics -

Social Media Mentions

StockTwits View RPRX Stock Mentions - StockTwits PennyStocks View RPRX Stock Mentions - PennyStockTweets
Twitter View RPRX Stock Mentions - Twitter Invest Hub View RPRX Investment Forum News - Investor Hub
Yahoo View RPRX Stock Mentions - Yahoo! Message Board Seeking Alpha View RPRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for RPRX - Insider Cow View Insider Transactions for RPRX - Insider Cow
CNBC View RPRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RPRX - OTC Markets
Yahoo View Insider Transactions for RPRX - Yahoo! Finance NASDAQ View Institutional Holdings for RPRX - NASDAQ

Stock Charts

FinViz View RPRX Stock Insight & Charts - StockCharts View RPRX Investment Charts -
BarChart View RPRX Stock Overview & Charts - BarChart Trading View View RPRX User Generated Charts - Trading View

Latest Financial News for RPRX

Repros Announces Negative Opinion From the EMA for Enclomiphene
Posted on Friday January 26, 2018

THE WOODLANDS, Texas, Jan. 26, 2018-- Repros Therapeutics Inc. ®, today announced that, consistent with the previously disclosed guidance from the European Medicines Agency, the CHMP, a committee of the ...

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division
Posted on Tuesday January 09, 2018

NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court Southern District of Texas Houston Division, case no. 4:17-cv-03918, on behalf of stockholders of Repros Therapeutics Inc. ("Repros" or the "Company") (RPRX) who held Repros securities and have been harmed by Repros and its board of directors' (the "Board") for alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the tender offer of Company common stock to be purchased by Allergan plc ("Allergan"). Under the terms of the agreement, Repros stockholders are only anticipated to receive $0.67 per share in cash in exchange for each share of Repros.  The complaint alleges that this offer is inadequate and alleges that the Schedule 14D-9 Solicitation/Recommendation Statement (the "Recommendation Statement") provides materially incomplete and misleading information about the Company's financials and the transaction, in violation of Sections 14(d)(4), 14(e), and 20(a) of the Exchange Act.

Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive Landscape
Posted on Thursday January 04, 2018

NEW YORK, Jan. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Athersys, ...

Repros Therapeutics Inc (NASDAQ:RPRX): Is Healthcare An Attractive Sector Play?
Posted on Friday December 29, 2017

Repros Therapeutics Inc (NASDAQ:RPRX), a USD$25.52M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...

Repros Announces Negative Opinion From the EMA for Enclomiphene
GlobeNewswire (press release) - Jan 26, 2018
THE WOODLANDS, Texas, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.®, (Nasdaq:RPRX) ("Repros" or the "Company") today announced that, consistent with the previously disclosed guidance from the European Medicines Agency (EMA), the CHMP ...
Accuray Incorporated (ARAY) registers a price change of 1.79% while Repros ... - Stocks Gallery

Repros Names Larry Dillaha, MD, its Permanent President and CEO
GlobeNewswire (press release) - Apr 10, 2017
Forward-looking statements include, but are not limited to, those relating to the Company's pipeline and plans for growth, and are subject to such risks as are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent ...
FDA continues partial clinical hold for Repros Therapeutics' fibroids drug - Seeking Alpha
Repros Therapeutics (RPRX) Says FDA Confirms Proellex Will Continue on Current ... -

Allergan to buy Woodlands-based drug company
Houston Business Journal - Dec 12, 2017
Pharmaceutical giant Allergan PLC (NYSE: AGN) will acquire The Woodlands-based Repros Therapeutics Inc. (Nasdaq: RPRX), a company that develops drugs to treat male and female reproductive disorders, according to a Dec. 12 press release.
REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, PA Announces ... - Business Wire (press release)

Repros' Proellex program to remain on partial clinical hold pending ...
Seeking Alpha - Jul 17, 2017
Nano cap Repros Therapeutics (NASDAQ:RPRX) craters 48% premarket on light volume in response to its announcement that the FDA will maintain its partial clinical hold on its Proellex (telapristone acetate) program after reviewing the existing liver ...
Repros Announces Proellex® Development Program Will Remain on Partial Clinical ... - GlobeNewswire (press release)
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Repros ... - Business Wire (press release)

Enter a stock symbol to view the stock details.